ACT Brief: Real-Time Monitoring Through Quick Wins, Consumer Wearable Validation Requirements, and Replimune RP1 Efficacy Data Advancement

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part five and final segment of his interview, Raviv Pryluk, CEO and co-founder of PhaseV, outlined a gradual, win-driven strategy for making real-time monitoring stick, starting in early phases and building toward pivotal trials with the right technology partners and a network effect that scales. Quick wins establish confidence and operational familiarity before broader rollout across therapeutic areas and study phases.
• In a contributed article from Signant Health, authors examined how consumer-grade wearables offer burden reduction and engagement benefits but show heterogeneous accuracy across devices and endpoints. Integration into regulated trials requires rigorous fit-for-purpose validation, careful endpoint selection, standardized use protocols, and ongoing performance monitoring to align data quality with regulatory expectations.
• FDA's advisory committee voted 10 to 3 that efficacy results from Replimune's Ignyte study are evaluable and clinically meaningful for RP1 in combination with nivolumab for anti-PD-1 refractory advanced melanoma. The favorable vote follows two prior complete response letters and supports the company's resubmitted biologics license application ahead of an August 2 target action date.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.